Moody Aldrich Partners LLC Merus N.V. Transaction History
Moody Aldrich Partners LLC
- $478 Million
- Q3 2025
A detailed history of Moody Aldrich Partners LLC transactions in Merus N.V. stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 76,444 shares of MRUS stock, worth $7.33 Million. This represents 1.51% of its overall portfolio holdings.
Number of Shares
76,444
Previous 92,009
16.92%
Holding current value
$7.33 Million
Previous $4.84 Million
48.73%
% of portfolio
1.51%
Previous 1.05%
Shares
5 transactions
Others Institutions Holding MRUS
# of Institutions
274Shares Held
63.8MCall Options Held
1.65MPut Options Held
758K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$420 Million13.26% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.54MShares$340 Million4.56% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$338 Million21.18% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.05MShares$292 Million5.34% of portfolio
-
Hbk Investments L P Dallas, TX2.85MShares$273 Million3.71% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $4.4B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...